Switch theme
Sign up to access all valuation multiples
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.
2010
18
Last FY Revenue $1K
LTM EBITDA -$3.0M
$7.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kancera has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$3.0M.
In the most recent fiscal year, Kancera achieved revenue of $1K and an EBITDA of -$4.8M.
Kancera expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kancera valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | $1K | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$3.0M | XXX | -$4.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -329721% | XXX | XXX | XXX |
| EBIT | -$3.0M | XXX | -$4.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -329721% | XXX | XXX | XXX |
| Net Profit | -$2.9M | XXX | -$4.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -318329% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kancera's stock price is SEK 1 (or $0).
Kancera has current market cap of SEK 122M (or $12.6M), and EV of SEK 76.2M (or $7.9M).
See Kancera trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.9M | $12.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kancera has market cap of $12.6M and EV of $7.9M.
Kancera's trades at 5444.4x EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Kancera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kancera has a P/E ratio of -4.3x.
See valuation multiples for Kancera and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.6M | XXX | $12.6M | XXX | XXX | XXX |
| EV (current) | $7.9M | XXX | $7.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 5444.4x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -2.6x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.3x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKancera's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.3M for the same period.
Kancera's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kancera's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kancera and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -329721% | XXX | XXX | XXX |
| EBITDA Growth | -39% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7664% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 285371% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 329821% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kancera acquired XXX companies to date.
Last acquisition by Kancera was XXXXXXXX, XXXXX XXXXX XXXXXX . Kancera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kancera founded? | Kancera was founded in 2010. |
| Where is Kancera headquartered? | Kancera is headquartered in Sweden. |
| How many employees does Kancera have? | As of today, Kancera has 18 employees. |
| Is Kancera publicy listed? | Yes, Kancera is a public company listed on STO. |
| What is the stock symbol of Kancera? | Kancera trades under KAN ticker. |
| When did Kancera go public? | Kancera went public in 2011. |
| Who are competitors of Kancera? | Similar companies to Kancera include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kancera? | Kancera's current market cap is $12.6M |
| Is Kancera profitable? | Yes, Kancera is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kancera? | Kancera's last 12 months EBITDA is -$3.0M. |
| What is the current EV/EBITDA multiple of Kancera? | Current EBITDA multiple of Kancera is -2.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
